Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 31, 2010, Pages 13608-13613

  Roy, Rituparna Sinha ^a,b   Soni, Shivani ^a,b   Harfouche, Rania ^a,b   Vasudevan, Pooja R ^b   Holmes, Oliver ^c   De Jonge, Hugo ^c   Rowed, Arthur ^c   Paraskar, Abhimanyu ^a,b   Hentschel, Dirk M ^a   Chirgadze, Dimitri ^e   Blundell, Tom L ^e   Gherardi, Ermanno ^c   Mashelkar, Raghunath A ^b,d   Sengupta, Shiladitya ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d NATIONAL CHEMICAL LABORATORY   (India)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cardiovascular disease; HGF SF; Ischemic disease; Nanoparticle; Protein engineering

Indexed keywords

MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; SCATTER FACTOR; SCATTER FACTOR 1K1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ISCHEMIA; MOUSE; NANOTECHNOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ENGINEERING; ZEBRA FISH; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; MOLECULAR GENETICS; NEOVASCULARIZATION (PATHOLOGY); PROTEIN QUATERNARY STRUCTURE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

DANIO RERIO; MURINAE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NANOTECHNOLOGY; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN ENGINEERING; PROTEIN STRUCTURE, QUATERNARY; ZEBRAFISH;

EID: 77956363290     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1006007107     Document Type: Article

References (32)

1. Rosamond W, et al. (2007) Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115:e69-e171.
2. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974.
3. Kutryk MJB, et al. (2001) Angiogenesis: an emerging technology for the treatment of coronary artery disease. Cardiology Rounds VI:1-8.
4. Fortuin FD, et al. (2003) One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 92:436-439.
5. Simons M, et al. (2002) Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. double-blind, randomized, controlled clinical trial. Circulation 105:793.
6. Yla-Herttuala S, et al. (2007) Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49:1015-1026.
7. Gupta R, et al. (2009) Human studies of angiogenic gene therapy. Cir Res 105:724-736.
8. Zhou X, et al. (2008) Fibronectin fibrillogenesis regulates three dimensional neovessel formation. Gene Dev 22:1231-1243.
9. Borman S (2006) Glycosylation engineering. Chem Eng News 84:13-22.
10. Sengupta S, et al. (2003) Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23:69-75.
11. Gherardi E, et al. (2006) Structural basis of hepatocyte growth factor/scatter factor and MET signaling. Proc Nat'l Assoc Sci USA 103:4046-4051.
12. Sengupta S, et al. (2003) Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation 107:2955-2961.
13. Ono K, et al. (1997) Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95:2552-2558.
14. Schwall RH, et al. (1996) Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. JCB 133:709-718.
15. Chirgadze DY, et al. (1999) Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 6:72-79.
16. Lietha D, et al. (2001) Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J 20:5543-5555.
17. Holmes O, et al. (2007) Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J Mol Biol 367:395-408.
18. Sengupta S, et al. (2004) Nitric oxide modulates hepatocyte growth factor/scatter factor-induced angiogenesis. Angiogenesis 7:285-294.
19. Richardson TP, et al. (2001) Polymeric system for dual growth factor delivery. Nat Biotechnol 19:1029-1034.
20. Hsieh PCH, et al. (2006) Local controlled intramycardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 114:637-644.
21. Kubo M, et al. (2009) Therapeutic neovascularization by nanotechnology-mediated cell- selective delivery of pitavastatin into the vascular endothelium. Arterioscler Thromb Vasc Biol 29:796-801.
22. Rocha FG, et al. (2008) The effect of sustained delivery of vascular endothelial growth factor on angiogenesis in tissue-engineered intestine. Biomaterials 29:2884-2890.
23. Chappell JC, et al. (2008) Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small 4:1769-1777.
24. Karihaloo A, et al. (2004) Hepatocyte growth factor-mediated renal epithelial branching morphogenesis is regulated by glypican-4 expression. Mol Cell Biol 24:8745-8752.
25. Rosario M, Birchmeier W (2003) How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 13:328-335.
26. Stoletov K, et al. (2007) High-resolution imaging of the dynamic tumor cell-vascular interface in transparent zebrafish. Proc Natl Acad Sci USA 104:17406-17411.
27. Ny A, et al. (2006) Zebrafish and Xenops tadpoles: small animal models to study angiogenesis and lymphangiogenesis. Exp Cell Res 312:684-693.
28. Wang N, et al. (2009) Effect of hepatocyte growth-promoting factors on myocardial ischemia during exercise in patients with severe coronary artery disease. Int Heart J 50:291-299.
29. Laham RJ, et al. (2001) Gene transfer for angiogenesis in coronary artery disease. Annual Rev Med 52:485-502.
30. Jin H, et al. (2003) Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. The Journal of Pharmacology and Experimental Therapeutics 304:654-660.
31. Van Belle E, et al. (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97:381-390.
32. Powell RJ, et al. (2008) Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 118:58-65.